Veterinary Medicine Information website

NOBIVAC IB MULTI+G+ND ΕΝΕΣΙΜΟ ΓΑΛΑΚΤΩΜΑ

Authorised
  • Infectious bronchitis virus, type Massachusetts, strain M41, Inactivated
  • Infectious bronchitis virus, strain D274, Inactivated
  • Infectious bursal disease virus, strain D78, Inactivated
  • Newcastle disease virus, strain Clone 30, Inactivated
Download as PDF

Product identification

Medicine name:
NOBIVAC IB MULTI+G+ND ΕΝΕΣΙΜΟ ΓΑΛΑΚΤΩΜΑ
Active substance:
  • Infectious bronchitis virus, type Massachusetts, strain M41, Inactivated
  • Infectious bronchitis virus, strain D274, Inactivated
  • Infectious bursal disease virus, strain D78, Inactivated
  • Newcastle disease virus, strain Clone 30, Inactivated
Target species:
  • Chicken
Route of administration:
  • Intramuscular use
  • Subcutaneous use

Product details

Active substance and strength:
  • Infectious bronchitis virus, type Massachusetts, strain M41, Inactivated
    4.00
    log2 virus neutralising unit(s)
    /
    1.00
    Dose
  • Infectious bronchitis virus, strain D274, Inactivated
    4.00
    log2 virus neutralising unit(s)
    /
    1.00
    Dose
  • Infectious bursal disease virus, strain D78, Inactivated
    12.50
    log2 virus neutralising unit(s)
    /
    1.00
    Dose
  • Newcastle disease virus, strain Clone 30, Inactivated
    50.00
    50% Protective Dose
    /
    1.00
    Dose
Pharmaceutical form:
  • Emulsion for injection
Withdrawal period by route of administration:
  • Intramuscular use
    • Chicken
      • Meat and offal
        0
        day
  • Subcutaneous use
    • Chicken
      • Meat and offal
        0
        day
Anatomical therapeutic chemical veterinary (ATCvet) codes:
  • QI01AA08
Legal status of supply:
  • Veterinary medicinal product subject to veterinary prescription
Authorisation status:
  • Valid
Authorised in:
  • Greece
Package description:

Additional information

Entitlement type:
  • Marketing Authorisation
Legal basis of product authorisation:
  • Complete application (stand-alone)
Marketing authorisation holder:
  • Intervet Hellas M.A.E.
Marketing authorisation date:
Manufacturing sites for batch release:
  • Intervet International B.V.
Responsible authority:
  • National Organization For Medicines
Authorisation number:
  • 14098/Κ-2710/13-04-1995/K-0095201
Date of authorisation status change: